Repligen (RGEN) announces the submission of a New Drug Application for SecreFlo, including a...

|About: Repligen Corporation (RGEN)|By:, SA News Editor

Repligen (RGEN) announces the submission of a New Drug Application for SecreFlo, including a request to receive priority review by the FDA. The firm says it plans to release initial results from a study on the ability of SecreFlo to detect pancreatic cancer in the first half of 2012.